ARCHIVES

In the Cancer Centers: Rosen Moves To City Of Hope

This article is from The Cancer Letter archive.

Vol. 39 No. 41 | November 1, 2013

Download PDF Visit The Full Archive

Related Articles

Campath Improves PFS In B-Cell CLL In Phase III Trial

January 26, 2007

NCI Remains Exception To NIH Authority Over Scientific Counselors

January 27, 1995

Avon Awards $50 Million To NCI And Three Centers.

October 12, 2001

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

The Future of Cancer Centers: Demographics Informatics, Genetics, Will BE Major Influences, Robert Young Says

May 7, 1999